Open Letter to Customers

To Our Partners:

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.

Our History

In the early 2000s, the pharmaceutical industry was facing a shift. Breakthrough scientific advances and the urgency to bring life-saving treatments to patients faster and more cost-effectively created a need for ones who could combine scientific excellence, speed, and scale with global collaboration. In this context, WuXi AppTec was born with a mission to serve as an "enabler" within the pharmaceutical health ecosystem, collaborating with ecosystem partners to lower the R&D cost, accelerating new drug research and development. When the company was established in 2000, there were just four founders and a single laboratory of 7,000 square feet, but with a bold dream that every drug can be made and every disease can be treated.

Enabling Innovation

For 25 years, WuXi AppTec's number one priority continues to be providing customers with resources and capabilities to advance discoveries in the life sciences and deliver treatments to those in need. From day one, our service platform was built to meet the stringent requirements from either customers or regulatory authorities. Globally, WuXi AppTec has won approvals by regulatory agencies in the U.S., EU, Australia, Canada, China, Japan, New Zealand, and Switzerland. We take pride in a strong track record of upholding the highest intellectual property (IP), data and privacy protection standards, as well as abiding by the laws and regulations in the countries in which we operate. It is this unwavering dedication that has earned us the trust in every partnership and brought us to where we are now. WuXi AppTec's strategy is clear: through "Follow the science," "Follow the customers," and "Follow the molecules," we continuously expanded capabilities to stay at the forefront of the industry and deliver value to customers and patients. Starting with laboratory chemical synthesis, the company progressively expanded its services to biology and testing, and from the early stage of drug discovery all the way to commercialization and manufacturing. WuXi AppTec launched synthetic chemistry services in 2001, followed by process development services in 2003. In 2004, the company initiated manufacturing services for research and development, while 2005 saw the beginning of bioanalytical services. In 2007, the company further enhanced its offerings by introducing toxicology and formulation services, with more campuses opened. The pursuit of better enabling our customers across different time zones and therapeutic areas is also mirrored in the strategic growth of global capacities and capabilities, which allows us to contribute to advancements in pharmaceutical innovation.

Global Footprint

For 25 years, WuXi AppTec's number one priority continues to be providing customers with resources and capabilities to advance discoveries in the life sciences and deliver treatments to those in need. From day one, our service platform was built to meet the stringent requirements from either customers or regulatory authorities. Globally, WuXi AppTec has won approvals by regulatory agencies in the U.S., EU, Australia, Canada, China, Japan, New Zealand, and Switzerland. We take pride in a strong track record of upholding the highest intellectual property (IP), data and privacy protection standards, as well as abiding by the laws and regulations in the countries in which we operate. It is this unwavering dedication that has earned us the trust in every partnership and brought us to where we are now. WuXi AppTec's strategy is clear: through "Follow the science," "Follow the customers," and "Follow the molecules," we continuously expanded capabilities to stay at the forefront of the industry and deliver value to customers and patients. Starting with laboratory chemical synthesis, the company progressively expanded its services to biology and testing, and from the early stage of drug discovery all the way to commercialization and manufacturing. WuXi AppTec launched synthetic chemistry services in 2001, followed by process development services in 2003. In 2004, the company initiated manufacturing services for research and development, while 2005 saw the beginning of bioanalytical services. In 2007, the company further enhanced its offerings by introducing toxicology and formulation services, with more campuses opened. The pursuit of better enabling our customers across different time zones and therapeutic areas is also mirrored in the strategic growth of global capacities and capabilities, which allows us to contribute to advancements in pharmaceutical innovation.

WuXi AppTec